What will Concerta do to mess you up
…dangerously high body temperatures, and/or the potential for cardiovascular failure or seizures. It provides a stimulant high. [ Source: http://www.chacha.com/question/what-will-concerta-do-to-mess-you-up ]
More Answers to “What will Concerta do to mess you up“
- What will Concerta do to mess you up
- dangerously high body temperatures, and/or the potential for cardiovascular failure or seizures. It provides a stimulant high.
- Is it possible to mess up my metabolism by taking concerta??
- Taking this drug will not damage your metabolism. Its very common for weight to fluctuate. When the medication is stopped, weight will most likely fluctuate again. What was the time frame in which you lost 10 pounds? Many people look to …
Related Questions Answered on Y!Answers
- Is it possible to mess up my metabolism by taking concerta?
- Q: It was prescribed to me for my severe ADHD.I’m a teen who has always had a very fast metabolism and a slim figure–my weight does not seem to fluctuate even when i get stoned and eat a gallon of ice cream with my friends. I don’t think I’ve ever gained a pound.I’ve been on 54 mg’s of time release concerta for about three weeks and I take a twenty mg ritalin as a study pill in the evenings. I would say I’ve lost about nine or ten pounds, which is back to the weight I was before I got depressed (which pertains to the ADHD, as it does in most cases). This is my natural weight.But will my metabolism have taken a blow from the effects of the meds? I’ve heard of people going on it for two years and losing like twenty pounds, then gaining practically fifty and never being able to go back again. If the meds are used as an accessory to rapid weight loss, is there a possibility of chronically damaging one’s metabolism?
- A: Ritalin and Concerta are pretty hardcore stimulants so you will lose weight while on them. When you quit, you will gain this back. I do not see why you would gain back more though.
- When taking concerta do the pros outweigh the cons or is it the other way around?
- Q: My doctor recently prescribed me concerta but I’m not sure if it is really safe to take it or not. Some of my friends say it is safe others say that there is a possibility it can really mess with my sleeping pattern and my mind.Can someone help me
- A: its a stimulant depending on the person it could keep you up all night and make you tweak out and stuff but if you take what the doctor gives you at the doses he tells you to its like 99.99% safe i do know people who have od’d on that stuff (at like ten times the doctors dose) though its called methylphenidate i think thats how its spelled look it up if you wanna know what it can do to youoh and everyone reacts different you gotta experiment with it to know if the pros weigh out the cons it works for some people and it doesnt for others
- What does it feel like on concerta or ridaline ?
- Q: My boyfriend has been messing around with prescription pills such as Concerta and ridaline – the drug is actually called methylphenidate the ADHD medicine, what happens if you take like more than your supposed to of them or sniff them if you are not prescribed to them .i just want to know what it feels like , he said it makes him feel really good but i think hes addicted to them .
- A: Common Side effectsNervousnessInsomniaLess common side effectsanorexianauseadizzinesspalpitationsheadachedyskinesiadrowsinesspulse and blood pressure changes, both up and downtachycardiaanginacardiac arrhythmiaabdominal painabnormal bleedingweight loss during prolonged therapyurticaria like rash and itchingDuring treatment of children, the following may occur more frequently:loss of appetiteabdominal painweight loss during prolonged therapyinsomniaKnown or suspected risks to healthResearchers have also looked into the role of methylphenidate in affecting stature, with some studies finding slight decreases in height acceleration. Other studies indicate height may normalize by adolescence. In a 2005 study, only “minimal effects on growth in height and weight were observed” after 2 years of treatment. “No clinically significant effects on vital signs or laboratory test parameters were observed.A 2003 study tested the effects of dextromethylphenidate (Focalin), levomethylphenidate, and (racemic) detro-, levomethylphenidate (Ritalin) on mice to search for any carcinogenic effects. The researchers found that all three preparations were non-genotoxic and non-clastogenic; d-MPH, d, l-MPH, and l-MPH did not cause mutations or chromosomal aberrations. They concluded that none of the compounds present a carcinogenic risk to humans.In February 2005, a team of researchers from The University of Texas M. D. Anderson Cancer Center led by R.A. El-Zein announced that a study of 12 children indicated that methylphenidate may be carcinogenic. In the study, 12 children were given standard therapeutic doses of methylphenidate. At the conclusion of the 3-month study, all 12 children displayed significant treatment-induced chromosomal aberrations. The researchers indicated that their study was relatively small and their results needed to be reproduced in a bigger population for a definitive conclusion about the genotoxicity of methylphenidate to be drawn.In response to the El-Zein study published in 2005, a team of six scientists from the Department of Child and Adolescent Psychiatry and Psychotherapy and the Department of Toxicology, University of Würzburg, Würzburg, Germany began a more in-depth study. They sought to respond to the challenge noted above to attempt to replicate the results of El-Zein et al. in a larger study. Their paper was completed in 2006 and published in 2007 in Environmental Health Perspectives (EHP), the peer-reviewed journal of the United States’ National Institute of Environmental Health Sciences. This study used a larger cohort and a longer period of follow-up and included a small group of long-term users, but otherwise used what researchers believed to be an identical methodology to that used by El-Zein et al. (They note that El-Zein et al. published a short study report and did not publish detailed descriptions of methodology.) After follow-ups at six months, the researchers found no evidence that methylphenidate might cause cancer, stating “the concern regarding a potential increase in the risk of developing cancer later in life after long-term MPH treatment is not supported”.The effects of long-term methylphenidate treatment on the developing brains of children with ADHD is the subject of study and debate.Although the safety profile of short-term methylphenidate therapy in clinical trials has been well established, repeated use of psychostimulants such as methylphenidate is less clear.The use of ADHD medication in children under the age of 6 has not been studied. Severe hallucinations may occur. ADHD symptoms include hyperactivity and difficulty holding still and following directions; these are also characteristics of a typical child under the age of 6. For this reason it may be more difficult to diagnose young children, and caution should be used with this age group.On March 22, 2006 the FDA Pediatric Advisory Committee decided that medications using methylphenidate ingredients do not need black box warnings about their risks, noting that “for normal children, these drugs do not appear to pose an obvious cardiovascular risk.”Previously, 19 possible cases had been reported of Cardiac arrest linked to children taking methylphenidate and the Drug Safety and Risk Management Advisory Committee to the FDA recommend a “black-box” warning in 2006 for stimulant drugs used to treat attention deficit/hyperactivity disorder.According to a small study conducted by the Society of Nuclear Medicine, the use of methylphenidate in certain individuals for reasons outside of its intended clinical applications may adversely affect cognitive performance. Specifically, methylphenidate positively affected brain glucose metabolism in subjects who performed well at baseline on an accuracy-controlled cognitive task, but caused further deterioration of mental processing in subjects who performed poorly at baseline. In other words, certain individuals without ADHD who take the drug to enhance concentration and focus may inadvertently make things worse.However, in a paper published in Biological Psychiatry (June 24, 2008 online), researchers report that methylphenidate fine-tunes the functioning of neurons in the prefrontal cortex – a brain region involved in attention, decision-making and impulse control – while having few effects outside it. The team studied PFC neurons in rats under a variety of methylphenidate doses, including one that improved the animals’ performance in a working memory task of the type that ADHD patients have trouble completing. Using microelectrodes, the scientists observed both the random, spontaneous firings of PFC neurons and their response to stimulation of the hippocampus. When they listened to individual PFC neurons, the scientists found that while cognition-enhancing doses of methylphenidate had little effect on spontaneous activity, the neurons’ sensitivity to signals coming from the hippocampus increased dramatically. Under higher, stimulatory doses, on the other hand, PFC neurons stopped responding to incoming information. Another study suggests that methylphenidate improves spatial orientation and working memory in rats on the radial arm maze.Scheduling and abuse potentialIt is generally accepted that methylphenidate is the closest pharmaceutical equivalent to cocaine, as studies have shown that cocaine addicts cannot distinguish between the two drugs when administered intravenously. However, cocaine has a much higher affinity for the dopamine receptor in comparison to methylphenidate, which is thought to be the mechanism of the euphoria associated with the cocaine high.In the United States, methylphenidate is classified as a Schedule II controlled substance, the designation used for substances that have a recognized medical value but present a high likelihood for abuse because of their addictive potential. Internationally, methylphenidate is a Schedule II drug under the Convention on Psychotropic Substances